<DOC>
	<DOCNO>NCT01725737</DOCNO>
	<brief_summary>Although psychostimulant first line drug treat Attention Deficit Hyperactivity Disorder , ( ADHD ) , actually 10-20 % ADHD patient response well current medication . Most parent child ADHD Taiwan dislike use psychostimulant . We expect GlyTI-M well efficacy placebo reduce ADHD symptom . This study also help u understand mechanism ADHD give way develop new drug also possible way treat ADHD child 6 year old .</brief_summary>
	<brief_title>Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>The accumulated neuro-image , hereditary animal study show correlation glutamate transport dysfunction ADHD psychopathology . However , limited clinical trial testify effect modulate NMDA receptor function glutamate treat ADHD . GlyTI-M endogenous Glycine transporter I inhibitor , act glutamatergic synapse modulate neurotransmission N-Methyl-D-Aspertate ( NMDA ) receptor . This study aim explore effect GlyTI-M among child ADHD .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>Fulfill criterion ADHD accord Diagnostic Statistic Manual , fourth edition ( DSMIV ) . Subjects parent agree participate study provide inform consent . Autism , Mental retardation . inability follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ADHD</keyword>
	<keyword>GlyTI-M</keyword>
</DOC>